Editorial: Triple-negative Breast Cancer: Heterogeneity, Tumor Microenvironment and Targeted Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 9

PMID 36483047

Authors

Xiyun Deng

Chanjuan Zheng

Faqing Tang

Thomas J Rosol

Zhi-Ming Shao

Affiliations

Soon will be listed here.

Citing Articles

Dysregulated Ribosome Biogenesis Is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 as a Key Mediator of the Stemness-inhibitory Effect of Lovastatin.

Zheng C, Yao H, Lu L, Li H, Zhou L, He X Int J Biol Sci. 2024; 20(6):2130-2148.

PMID: 38617541 PMC: 11008279. DOI: 10.7150/ijbs.94058.

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology.

Chaudhuri A, Kumar D, Dehari D, Patil R, Singh S, Kumar D Cancers (Basel). 2023; 15(9).

PMID: 37174125 PMC: 10177107. DOI: 10.3390/cancers15092661.

References

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Shi P, Liu W, Tala , Wang H, Li F, Zhang H . Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017; 3:17010. PMC: 5396048. DOI: 10.1038/celldisc.2017.10. View

Liu J, Li Y, Li Q, Liang D, Wang Q, Liu Q . Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Cancer Res Treat. 2021; 186(3):687-697. DOI: 10.1007/s10549-021-06128-4. View

Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W . Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics. 2016; 6(4):533-44. PMC: 4775863. DOI: 10.7150/thno.14315. View

Liu Z, Mi M, Zheng X, Zhang C, Zhu F, Liu T . miR-30a/SOX4 Double Negative Feedback Loop is modulated by Disulfiram and regulates EMT and Stem Cell-like properties in Breast Cancer. J Cancer. 2021; 12(16):5053-5065. PMC: 8247377. DOI: 10.7150/jca.57752. View

Singh D, Yadav D . TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedicines. 2021; 9(8). PMC: 8389539. DOI: 10.3390/biomedicines9080876. View

Vafaei S, Zekiy A, Khanamir R, Zaman B, Ghayourvahdat A, Azimizonuzi H . Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022; 22(1):2. PMC: 8725311. DOI: 10.1186/s12935-021-02407-8. View

Luo L, Keyomarsi K . PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022; 31(6):607-631. PMC: 9296104. DOI: 10.1080/13543784.2022.2067527. View

Versini A, Colombeau L, Hienzsch A, Gaillet C, Retailleau P, Debieu S . Salinomycin Derivatives Kill Breast Cancer Stem Cells by Lysosomal Iron Targeting. Chemistry. 2020; 26(33):7416-7424. DOI: 10.1002/chem.202000335. View

10.

Wojtukiewicz M, Pogorzelska M, Politynska B . Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?. Cancer Metastasis Rev. 2022; 41(3):465-469. PMC: 9470645. DOI: 10.1007/s10555-022-10060-4. View

11.

Xie J, Zou Y, Ye F, Zhao W, Xie X, Ou X . A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer. Front Cell Dev Biol. 2022; 9:795600. PMC: 8790231. DOI: 10.3389/fcell.2021.795600. View

12.

Mir M, Qayoom H, Mehraj U, Nisar S, Bhat B, Wani N . Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer. Curr Cancer Drug Targets. 2020; 20(8):586-602. DOI: 10.2174/1570163817666200518081955. View

13.

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

14.

Savas P, Loi S . Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer. Cancer Cell. 2020; 37(5):623-624. DOI: 10.1016/j.ccell.2020.04.007. View

15.

Parsons H, Beaver J, Cimino-Mathews A, Ali S, Axilbund J, Chu D . Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2016; 23(2):379-386. PMC: 5241251. DOI: 10.1158/1078-0432.CCR-16-1543. View

16.

McGuinness J, Kalinsky K . Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opin Biol Ther. 2020; 21(7):903-913. DOI: 10.1080/14712598.2021.1840547. View

17.

Huang R, Haberberger J, Severson E, Duncan D, Hemmerich A, Edgerly C . A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Mod Pathol. 2020; 34(2):252-263. DOI: 10.1038/s41379-020-00664-y. View

18.

Bai X, Ni J, Beretov J, Graham P, Li Y . Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?. Cancer Lett. 2020; 497:100-111. DOI: 10.1016/j.canlet.2020.10.016. View